80% Of Cerezyme Patients Have Returned Since Shipments Resumed, Genzyme Says
This article was originally published in The Pink Sheet Daily
Executive Summary
At J.P. Morgan conference, CEO Termeer says manufacturing problems are in the past and priorities include building redundant capacity to avoid any future shortages.
You may also be interested in...
Genzyme Institutes Further Rationing Of Cerezyme, Fabrazyme To Build Inventory
Despite last year's manufacturing problems and the resulting shortages, biotech says 85 percent of U.S. Cerezyme patients have returned.
Genzyme Institutes Further Rationing Of Cerezyme, Fabrazyme To Build Inventory
Despite last year's manufacturing problems and the resulting shortages, biotech says 85 percent of U.S. Cerezyme patients have returned.
With Activist Investors Looming, Genzyme Takes Preventive Steps
Mutual cooperation agreement with top institutional investor and hiring of a new head of global product quality may be intended to stave off a potential proxy fight.